BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28300564)

  • 1. Contrasting roles of the ABCG2 Q141K variant in prostate cancer.
    Sobek KM; Cummings JL; Bacich DJ; O'Keefe DS
    Exp Cell Res; 2017 May; 354(1):40-47. PubMed ID: 28300564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of the ABCG2 C421A polymorphism with prostate cancer risk and survival.
    Gardner ER; Ahlers CM; Shukla S; Sissung TM; Ockers SB; Price DK; Hamada A; Robey RW; Steinberg SM; Ambudkar SV; Dahut WL; Figg WD
    BJU Int; 2008 Dec; 102(11):1694-9. PubMed ID: 18710444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer resistance protein (BCRP)-mediated glyburide transport: effect of the C421A/Q141K BCRP single-nucleotide polymorphism.
    Pollex EK; Anger G; Hutson J; Koren G; Piquette-Miller M
    Drug Metab Dispos; 2010 May; 38(5):740-4. PubMed ID: 20159988
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCRP/
    Wen X; Kozlosky D; Zhang R; Doherty C; Buckley B; Barrett E; Aleksunes LM
    Drug Metab Dispos; 2021 Aug; 49(8):629-637. PubMed ID: 34074729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single nucleotide polymorphisms modify the transporter activity of ABCG2.
    Morisaki K; Robey RW; Ozvegy-Laczka C; Honjo Y; Polgar O; Steadman K; Sarkadi B; Bates SE
    Cancer Chemother Pharmacol; 2005 Aug; 56(2):161-72. PubMed ID: 15838659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2.
    Mizuarai S; Aozasa N; Kotani H
    Int J Cancer; 2004 Mar; 109(2):238-46. PubMed ID: 14750175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The frequency of rs2231142 in
    Alrajeh K; Roman YM
    Pharmacogenomics; 2023 Jan; 24(1):15-26. PubMed ID: 36651271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential role of the ABCG2-Q141K polymorphism in type 2 diabetes.
    Szabó E; Kulin A; Mózner O; Korányi L; Literáti-Nagy B; Vitai M; Cserepes J; Sarkadi B; Várady G
    PLoS One; 2021; 16(12):e0260957. PubMed ID: 34855903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Q141K on the Transport of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors by ABCG2.
    Inoue Y; Morita T; Onozuka M; Saito KI; Sano K; Hanada K; Kondo M; Nakamura Y; Kishino T; Nakagawa H; Ikegami Y
    Cells; 2019 Jul; 8(7):. PubMed ID: 31340525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro identification of decreased function phenotype ABCG2 variants.
    Suominen L; Sjöstedt N; Vellonen KS; Gynther M; Auriola S; Kidron H
    Eur J Pharm Sci; 2023 Sep; 188():106527. PubMed ID: 37451410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone chemotherapy.
    Kim IS; Kim HG; Kim DC; Eom HS; Kong SY; Shin HJ; Hwang SH; Lee EY; Lee GW
    Cancer Sci; 2008 Dec; 99(12):2496-501. PubMed ID: 19032367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations.
    Furukawa T; Wakabayashi K; Tamura A; Nakagawa H; Morishima Y; Osawa Y; Ishikawa T
    Pharm Res; 2009 Feb; 26(2):469-79. PubMed ID: 18958403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The C421A (Q141K) polymorphism enhances the 3'-untranslated region (3'-UTR)-dependent regulation of ATP-binding cassette transporter ABCG2.
    Ripperger A; Benndorf RA
    Biochem Pharmacol; 2016 Mar; 104():139-47. PubMed ID: 26903388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
    Li J; Cusatis G; Brahmer J; Sparreboom A; Robey RW; Bates SE; Hidalgo M; Baker SD
    Cancer Biol Ther; 2007 Mar; 6(3):432-8. PubMed ID: 17312388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone deacetylase inhibitors influence chemotherapy transport by modulating expression and trafficking of a common polymorphic variant of the ABCG2 efflux transporter.
    Basseville A; Tamaki A; Ierano C; Trostel S; Ward Y; Robey RW; Hegde RS; Bates SE
    Cancer Res; 2012 Jul; 72(14):3642-51. PubMed ID: 22472121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells.
    Liu H; Song X; Hou J; Zhao Z; Chang J
    DNA Cell Biol; 2018 Mar; 37(3):210-219. PubMed ID: 29327946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-evaluation and functional classification of non-synonymous single nucleotide polymorphisms of the human ATP-binding cassette transporter ABCG2.
    Tamura A; Wakabayashi K; Onishi Y; Takeda M; Ikegami Y; Sawada S; Tsuji M; Matsuda Y; Ishikawa T
    Cancer Sci; 2007 Feb; 98(2):231-9. PubMed ID: 17297656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the gout-causing Q141K polymorphism and a CFTR ΔF508 mimicking mutation on the processing and stability of the ABCG2 protein.
    Sarankó H; Tordai H; Telbisz Á; Özvegy-Laczka C; Erdős G; Sarkadi B; Hegedűs T
    Biochem Biophys Res Commun; 2013 Jul; 437(1):140-5. PubMed ID: 23800412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study.
    Tian C; Ambrosone CB; Darcy KM; Krivak TC; Armstrong DK; Bookman MA; Davis W; Zhao H; Moysich K; Gallion H; DeLoia JA
    Gynecol Oncol; 2012 Mar; 124(3):575-81. PubMed ID: 22112610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.